Contact Us
Drug Search Results
More Filters [+]

U3-1565

Alternative Names: u3-1565, u3 1565, u31565
Latest Update: 2014-05-19
Latest Update Note: Clinical Trial Update

Product Description

For Advanced Solid Malignant Tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01290471)

Mechanisms of Action: HBEGF Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for U3-1565

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Ovarian Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JapicCTI-111484

P1

Completed

Oncology Solid Tumor Unspecified

2014-03-31

U31565-A-U101

P1

Completed

Ovarian Cancer

2013-01-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions